Obicetrapib
Obicetrapib, the rebirth of CETP inhibitors? A review of ROSE and ROSE2 phase 2 data ahead of four ongoing phase 3 trials (Curr Atheroscler Rep 2024)
Original title: Obicetrapib-the Rebirth of CETP Inhibitors?
A perspective review on the development status of obicetrapib, a third-generation CETP inhibitor, following positive phase 2 results. The ROSE and ROSE2 trials tested obicetrapib added to pre-existing high-intensity statin therapy and found significant reductions in LDL-C, apoB and non-HDL-C alongside a rise in HDL-C. Four phase 3 trials, including a cardiovascular outcomes trial, were ongoing at the time of writing. The authors describe preliminary safety data as showing no significant signals and note that favourable lipid effects could theoretically translate into fewer ASCVD events, pending confirmation from the phase 3 programme.
Original abstract
Purpose Of Review: To provide perspective on the current development status, and potential future role, of obicetrapib, a third-generation cholesterylester transfer protein (CETP) inhibitor. Obicetrapib has received recent attention following positive Phase II clinical trial data and initiation of Phase III trials for the treatment of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).
Recent Findings: The ROSE and ROSE2 trials are Phase II studies that examined the lipid lowering effects of obicetrapib in patients on pre-existing high-intensity statin therapy. Obicetrapib significantly reduced key dyslipidemia biomarkers including low density lipoprotein cholesterol (LDL-C), Apolipoprotein B (Apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) while increasing high-density lipoprotein cholesterol (HDL-C). Four phase III clinical trials, including a cardiovascular outcomes trial, are ongoing. Preliminary data for obicetrapib shows favorable effects on dyslipidemia, which could theoretically lead to a decrease in ASCVD clinical events. Short-term safety data in preliminary studies shows no significant safety signals.
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.